IQVIA Holdings Inc. IQV
270.37
(4.65)
(1.69%)
as of 25 Sep
- Market cap
- $45.3B
- P/E
- 33.3×
Follow IQV
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
IQVIA Holdings Inc. (IQV) P/E ratio
As of 25 September 2026, IQVIA Holdings Inc. (IQV) trades at a P/E ratio of 33.3×. Over the past ten years it has ranged from 15.1× (February 2018) to 246× (September 2020); the current reading is higher than 51% of that period. That is in line with the Diagnostics & Research industry median of 33.9× and above the Healthcare sector median of 22.7×.
P/E ratio, daily
Annual
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 28.4× | 9.64% |
| FY2024 | 25.9× | (16.62%) |
| FY2023 | 31.1× | (11.39%) |
| FY2022 | 35.1× | (37.20%) |
| FY2021 | 55.9× | (54.47%) |
| FY2020 | 123× | (22.16%) |
| FY2019 | 158× | 72.36% |
| FY2018 | 91.5× | 479.80% |
| FY2017 | 15.8× | (64.93%) |
| FY2016 | 45.0× | 106.40% |
Quarterly
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 23.8× | 13.44% |
| Mar 2026 | 21.0× | (26.29%) |
| Dec 2025 | 28.4× | 9.99% |
| Sep 2025 | 25.8× | 14.46% |
| 42 more quarters | Free account |
Against its own ten years
Low 15.1×
High 246×
Ten-year median
32.9×
Current reading's percentile
51
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NTRA Natera, Inc. compare | n/m |
| GH Guardant Health, Inc. compare | n/m |
| DGX Quest Diagnostics Incorporated compare | 24.8× |
| IQV IQVIA Holdings Inc. | 33.3× |
| MTD Mettler-Toledo International, Inc. compare | 33.9× |
| A Agilent Technologies, Inc. compare | 33.9× |
| IDXX IDEXX Laboratories, Inc. compare | 36.2× |
| ILMN Illumina, Inc. compare | 50.4× |
| WAT Waters Corporation compare | 108× |
| Diagnostics & Research industry median | 33.9× |
| Healthcare sector median | 22.7× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on IQV
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement